Raymond James lowered the firm’s price target on Revvity (RVTY) to $115 from $120 and keeps an Outperform rating on the shares. While Revvity had a “solid” Q2 report, reimbursement headwinds in China will weigh on growth for the rest of the year, the analyst tells investors in a research note. The firm thinks shares are undervalued and continues to see ~6% out-year organic growth with expanding margins that are underappreciated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity’s Strategic Measures and Strong Software Performance Justify Buy Rating Despite FY25 Challenges
- Revvity’s Resilience: Strong Performance and Growth Opportunities Amidst Challenges
- Revvity, Inc. Earnings Call: Mixed Sentiment and Strategic Moves
- Revvity falls -9.0%
- U.S. strikes EU trade deal, Samsung to make AI6 chips for Tesla: Morning Buzz